Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice

Abstract

CD3-Ab treatment induced rapid regression of established atherosclerosis via reducing CD4(+) T cells and increasing the proportion of Tregs. These findings suggest that therapeutic intervention for T-cell-mediated immune responses may represent a novel strategy to induce atherosclerosis regression in combination with lipid-lowering therapy.

Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases

“…7 Although not yet successful, therapeutic interventions targeting the atherosclerotic inflammatory process described may lead to establishment of definitive treatments for atherosclerotic CVD. [9][10][11][12][13][14] Intestine as a Therapeutic Target for Preventing Atherosclerosis…”

The Role of Inflammation in Myocardial Infarction

“…One of these potential targets is CD3, which seems to play a major role in recruitment of inflammatory cells to the developing plaque. Administration of anti-CD3 antibody in mice that had already developed atherosclerosis demonstrated a regression of atherosclerosis and reduced accumulation of macrophages and CD4 + T-cells in the plaques, whereas the Treg population was increased [188]. Another possible candidate is IL-19.…”

Increased PTPN22 Expression and Defective CREB Activation Impair Regulatory T-Cell Differentiation in Non-ST-Segment Elevation Acute Coronary Syndromes

“…Inflammation plays a key role in atherosclerotic plaque initiation and progression (1,2). In experimental models of atherogenesis, reduced frequency of regulatory T cells (Treg), the helper T-cell compartment involved in peripheral tolerance, promotes atherosclerosis, while increased Treg response induces regression of atherosclerosis and stabilization of plaque (3).…”